169 related articles for article (PubMed ID: 28933918)
1. Pharmacokinetics of a New Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder.
Sikes CR; McMahen RL; Stark JG; Engelking D
J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):29-35. PubMed ID: 28933918
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
Stark JG; Engelking D; McMahen R; Sikes C
J Child Adolesc Psychopharmacol; 2017 Apr; 27(3):216-222. PubMed ID: 27936898
[TBL] [Abstract][Full Text] [Related]
3. A randomized crossover study to assess the pharmacokinetics of a novel amphetamine extended-release orally disintegrating tablet in healthy adults.
Stark JG; Engelking D; McMahen R; Sikes C
Postgrad Med; 2016 Sep; 128(7):648-55. PubMed ID: 27488574
[TBL] [Abstract][Full Text] [Related]
4. A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
Childress A; Newcorn J; Stark JG; McMahen R; Tengler M; Sikes C
J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):505-12. PubMed ID: 27228207
[TBL] [Abstract][Full Text] [Related]
5. An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children.
Marraffino A; Sikes CR; Laage T; Volosov A; Hart A; Engelking D
J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):15-20. PubMed ID: 31295008
[No Abstract] [Full Text] [Related]
6. Pharmacokinetics of a New Amphetamine Extended-release Oral Liquid Suspension Under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-label, Single-dose, 3-treatment Study.
Sikes C; Stark JG; McMahen R; Engelking D
Clin Ther; 2017 Dec; 39(12):2389-2398. PubMed ID: 29174216
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, Safety, and Tolerability of SHP465 Mixed Amphetamine Salts After Administration of Multiple Daily Doses in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder.
Ilic K; Kugler AR; Yan B; McNamara N
CNS Drugs; 2022 Jan; 36(1):71-81. PubMed ID: 34826114
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Phase I Study to Assess the Effect of Alcohol on the Pharmacokinetics of an Extended-release Orally Disintegrating Tablet Formulation of Amphetamine in Healthy Adults.
Newcorn JH; Stark JG; Adcock S; McMahen R; Sikes C
Clin Ther; 2017 Aug; 39(8):1695-1705. PubMed ID: 28760535
[TBL] [Abstract][Full Text] [Related]
9. Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder.
Childress A; Mehrotra S; Gobburu J; McLean A; DeSousa NJ; Incledon B
J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):10-18. PubMed ID: 29039979
[TBL] [Abstract][Full Text] [Related]
10. A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR
Adjei AL; Chaudhary I; Kollins SH; Padilla A
Paediatr Drugs; 2020 Oct; 22(5):561-570. PubMed ID: 32776159
[TBL] [Abstract][Full Text] [Related]
11. Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD.
Childress AC; Sallee FR; Berry SA
Postgrad Med; 2011 Sep; 123(5):80-8. PubMed ID: 21904089
[TBL] [Abstract][Full Text] [Related]
12. Amphetamine extended-release oral suspension for attention-deficit/hyperactivity disorder.
Childress AC; Chow H
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):965-971. PubMed ID: 31526076
[No Abstract] [Full Text] [Related]
13. Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect.
Caras S; Sharpe T
J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):69-80. PubMed ID: 31809216
[No Abstract] [Full Text] [Related]
14. Fed and Fasted Administration of a Novel Extended-Release Methylphenidate Orally Disintegrating Tablet Formulation for the Treatment of ADHD.
Weisler RH; Stark JG; Sikes C
Clin Pharmacol Drug Dev; 2018 Feb; 7(2):160-167. PubMed ID: 28544344
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study.
Boellner SW; Stark JG; Krishnan S; Zhang Y
Clin Ther; 2010 Feb; 32(2):252-64. PubMed ID: 20206783
[TBL] [Abstract][Full Text] [Related]
16. Effects of Food on the Bioavailability of Amphetamine in Healthy Adults After Administration of SHP465 Mixed Amphetamine Salts Extended-Release Capsules.
Wang Y; Yu M; Yan B; Martin P; Robertson B
Drugs R D; 2019 Jun; 19(2):167-175. PubMed ID: 30911906
[TBL] [Abstract][Full Text] [Related]
17. The Clinical Pharmacokinetics of Amphetamines Utilized in the Treatment of Attention-Deficit/Hyperactivity Disorder.
Markowitz JS; Patrick KS
J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):678-689. PubMed ID: 28910145
[TBL] [Abstract][Full Text] [Related]
18. A Comparison of the Pharmacokinetics of Methylphenidate Extended-Release Orally Disintegrating Tablets With a Reference Extended-Release Formulation of Methylphenidate in Healthy Adults.
Childress A; Stark JG; McMahen R; Engelking D; Sikes C
Clin Pharmacol Drug Dev; 2018 Feb; 7(2):151-159. PubMed ID: 28544581
[TBL] [Abstract][Full Text] [Related]
19. A Single-Dose, Two-Way Crossover, Open-Label Bioequivalence Study of an Amphetamine Extended-Release Oral Suspension in Healthy Adults.
Sikes C; Stark JG; McMahen R; Engelking D
J Atten Disord; 2020 Feb; 24(3):414-419. PubMed ID: 29192549
[No Abstract] [Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of edivoxetine (LY2216684), a norepinephrine reuptake inhibitor, in pediatric patients with attention-deficit/hyperactivity disorder.
Kielbasa W; Quinlan T; Jin L; Xu W; Lachno DR; Dean RA; Allen AJ
J Child Adolesc Psychopharmacol; 2012 Aug; 22(4):269-76. PubMed ID: 22849510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
